Several ribosomal proteins regulate p53 function by modulating MDM2. We recently found that RPS27L, a RPS27-like protein, is a direct p53-inducible target. Here we showed that RPS27 itself is a p53-repressible target. Furthermore, the N-terminal region of either RPS27L or RPS27 binds to MDM2 on the central acidic domain of MDM2. RPS27L or RPS27 forms an in vivo triplex with MDM2-p53 and competes with p53 for MDM2 binding. Similar to p53, RPS27L, but not RPS27, is a short-lived protein and a novel MDM2 substrate. Degradation of RPS27L requires the RING or acidic domain of MDM2. Ectopic expression of RPS27L or RPS27 inhibits MDM-2-mediated p53 ubiquitination and increases p53 levels by extending p53 protein half-life, whereas siRNA silencing of RPS27L decreases p53 levels by shortening p53 half-life, with a corresponding reduction in p53 transcription activity. RPS27L is mainly localized in the cytoplasm, but upon p53-activating signals, a portion of RPS27L shuttled to the nucleoplasm where it colocalizes with MDM2. Both the cytoplasmic and the nuclear p53, induced by ribosomal stress, were reduced upon RPS27L silencing. Our study reveals a multilevel interplay between RPS27L/S27 and p53-MDM2 axis, with RPS27L functioning as a p53 target, a MDM2 substrate and a p53 regulator.
Introduction
The primary role of ribosomal proteins is to assemble with rRNA for new protein synthesis. The entire ribosome, consisting of four rRNA species (5S, 5.8S, 18S and 28S) and approximately 75 ribosomal proteins, is first assembled in the nucleolus as two precursor subunits (40S small subunit and 60S large subunit). The ribosomal precursors then move to the cytoplasm for complete processing into ribosomes and polysomes for protein synthesis. The mature 40S ribosomal subunit contains the 18S rRNA and B32 ribosomal proteins, whereas the 60S ribosomal subunit consists of the 5S, 5.8S and 28S rRNA and B45 ribosomal proteins (Kressler et al., 1999; Venema and Tollervey, 1999) . Recently, some ribosomal proteins, such as L5, L11, L23 and S7, were found to regulate cell cycle progression and apoptosis through binding to and inhibiting MDM2, leading to activation of the p53 tumor suppressor (Lohrum et al., 2003; Zhang et al., 2003; Bhat et al., 2004; Jin et al., 2004; Chen et al., 2007; Lindstrom et al., 2007; Zhang and Lu, 2009; Zhu et al., 2009) . Thus, some ribosomal proteins have an extended role in addition to protein synthesis. RPS27L (NM_015920) is an uncharacterized novel protein, which was recently identified as a p53-inducible target by our group (He and Sun, 2007) and confirmed by another group . RPS27L differs from its family member RPS27 (ribosomal protein S27) (NM_001030) by only three amino acids (AA) (R5K, L12P and K17R) at the N-terminus. Human RPS27L and RPS27 were mapped onto chromosomes 15q22.1 and 1q21, respectively, whereas mouse RPS27L and RPS27 were mapped onto chromosomes 9 and 3, respectively. The similarity of these two RPS27L and RPS27 loci at the AA level suggests that either RPS27 or RPS27L arose by duplication of the other locus (Balasubramanian et al., 2009) .
Although little is known about RPS27L, a number of studies have revealed the cancer relevance of its family member, RPS27. RPS27, also called metallopanstimulin-1 (MPS-1), was first identified as a growth factorinducible gene, which encodes a 9.5 kDa protein of 84 AAs with a zinc-finger-like motif (Chan et al., 1993; Fernandez-Pol et al., 1993; Wong et al., 1993) . RPS27/ MPS-1 is overexpressed in large quantities in various proliferating tissues (Fernandez-Pol et al., 1994) and in multiple human cancers, including carcinomas of colon (Ganger et al., 1997) , prostate , breast (Atsuta et al., 2002) , liver (Ganger et al., 2001) , stomach (Wang et al., 2006) , and head and neck . A recent study showed that RPS27/ MPS-1 was overexpressed in 86% of gastric cancer tissues, and that its overexpression correlated with late stage of the disease (Wang et al., 2006) . SiRNA silencing of RPS27/MPS-1 in a gastric cancer cell line, induced spontaneous apoptosis, and inhibited cell growth in monolayer cultures and in nude mouse xenograft tumors (Wang et al., 2006) . Furthermore, when overexpressed in cancer tissues, RPS27/MPS-1 is released by secretion or gradient diffusion into the extracellular space, which allows for its measurement in serum . Upon release, RPS27/MPS-1 binds to albumin present in serum and can be detected either by radioimmunoassay or by western blotting as a 75 kDa band (FernandezPol, 1996; Lee et al., 2004) . The level of RPS27/MPS-1 was found to be elevated in the sera of patients, with various types of common cancers (Fernandez-Pol, 1996; Lee et al., 2004; Stack et al., 2004) . It was, therefore, proposed that RPS27/MPS-1 can serve as a tumor marker, particularly for head and neck squamous cell carcinoma (Fernandez-Pol, 1996; Lee et al., 2004; Stack et al., 2004) . However, the molecular mechanisms of RPS27 and RPS27L action remain largely elusive.
Here, we report an interesting interplay between p53, MDM2 and RPS27L or RPS27. It is well established that p53-MDM2 forms a negative autoregulatory feedback loop in which p53 transactivates MDM2, whereas an induced MDM2 binds to p53 and promotes p53 degradation (Wu et al., 1993) . RPS27L and RPS27 join this axis as a target, as a substrate or as a regulator of p53-MDM2. First, in contrast to RPS27L, which is subjected to p53 induction (He and Sun, 2007; Li et al., 2007) , RPS27 is a p53-repressed gene, indicating that such as MDM2, both ribosomal proteins are p53 downstream targets. Second, either RPS27L or RPS27 binds to MDM2, and was subjected, particularly RPS27L, to Mdm-2-mediated ubiquitination and degradation. Third, either RPS27L or RPS27 competes with p53 for MDM2 binding, and consequently, inhibiting MDM2-mediated p53 ubiquitination and degradation. Fourth, although ectopic expression of RPS27L or RPS27 increases p53 levels, siRNA silencing of RPS27L but not RPS27 destabilizes p53. Finally, RPS27L is mainly localized in cytoplasm under unstressed condition, but a portion of RPS27L is shuttled to nucleus on DNA damage and ribosomal stress, where it colocalized with MDM2. Both the cytoplasmic and the nucleoplasmic p53, induced by actinomycin D, were attenuated upon RPS27L silencing. Taken together, our study showed that although several ribosomal proteins have been previously shown to bind and inhibit MDM2 for p53 activation (Lindstrom et al., 2007; Lu, 2009), with RPS7 and RPL26 being MDM2 substrates (Ofir-Rosenfeld et al., 2008; Zhu et al., 2009 ), RPS27 and RPS27L are the first class of ribosomal or ribosomal-like proteins that are direct p53 targets as well as MDM2 substrate (in case of RPS27L), and that regulate p53 through MDM2.
Results

RPS27
and RPS27L are evolutionarily conserved proteins RPS27 and its family member, RPS27L are 84 AAscontaining proteins with a zinc-finger-like domain. Two family members differ from each other by only three AAs (R5K, L12P and K17R) at the N-terminus ( Figure 1a) . We compared the protein sequences of RPS27 and RPS27L in more than 10 species. As shown in Figure 1b , both family members are highly conserved during evolution, suggesting their functional significance. In addition to human, the R5K/L12P/K17R conservation of two family members is also found in mouse, rat and dog. Like in humans, there are two members of RPS27/S27L family in yeast Saccharomyces cerevisiae, RPS27A (YKL156W) and RPS27B (YHR021C), differing by only one AA at codon 62 (I62V). The yeast with systematic deletion of either RPS27A or RPS27B is still viable, although deletion of RPS27B showed some growth defect (Giaever et al., 2002) (also see http://www.yeastgenome.org). In Caenorhabditis elegans, however, there is only one family member (RPS27). SiRNA silencing leads to embryonic lethality (Sonnichsen et al., 2005) (also see http://elegans.swmed.edu). In Drosophila, one family member is identified. Its molecular function is described as structural constituent of ribosome, nucleic acid binding (see http://flybase.bio.indiana.edu/reports/ FBgn0039300.html) and it is involved in the biological process of translation.
To selectively detect endogenous RPS27L and RPS27, we generated and affinity-purified two antibodies specifically against either one of the family members. As shown in Figure 1c , the RPS27L antibody detected both endogenous and HA-tagged RPS27L (S27L-HA), but not HA-tagged RPS27 (S27-HA) (top panel), whereas the RPS27 antibody detected both endogenous and S27-HA but not S27L-HA (second panel). As expected, anti-HA tag antibody detected both S27L-HA and S27-HA (third panel). Thus, two antibodies are specific for their corresponding proteins, and do not crossreact with each other.
RPS27 is a p53-repressible gene We previously showed that RPS27L is a p53 target, subjecting to p53 induction (He and Sun, 2007) , which was later confirmed by others . During our parallel study of p53 regulation of RPS27L and RPS27, we found that in contrast to RPS27L, RPS27 was actually repressed by p53. As shown in Figure 2a , treatment with etoposide, a DNA-damaging agent, which induced p53 and its downstream targets p21 and RPS27L, significantly reduced the level of RPS27 in wild-type (wt) p53-containing HCT116 cells (lane 1 vs 2), but only a slight reduction of RPS27 was seen in p53-null HCT116 cells (lanes 3 and 4). The p53-dependent repression of RPS27 was further demonstrated in wt p53-containing A549 cells. As shown in Figure 2b , in A549 cells, infected with control siRNA, the basal level of RPS27 was very high, but remarkably reduced upon p53 activation by MI-219, a small molecule that disrupts the p53-MDM2 binding (Shangary et al., 2008) , or etoposide (lanes 1-3). The p53-induced RPS27 repression was abrogated if p53 was silenced by siRNA (lanes 4-6). We further confirmed that p53-induced RPS27 repression occurred at the transcriptional level, as demonstrated by RT-qPCR analysis ( Figure 2c ). Finally, we used the H1299-p53 temperature-sensitive model (Peng et al., 2003; Robinson et al., 2003) , and showed that although MDM2 and RPS27L were induced when cells were grown at the permissive 32 1C (wt p53 conformation), RPS27 expression was repressed. No difference was seen among these proteins, at 37 1C, with a mutant p53 confirmation (Figure 2d , top panel). Neither RPS27 reduction nor RPS27L induction was due to cold shock, as the same treatment in p53-null H1299-neo control cells, even slightly, increased the RPS27 levels but had no effect on RPS27L (Figure 2d , bottom panel). Our results demonstrate that RPS27 is a p53-repressible gene.
RPS27L or RPS27 binds to MDM2 in vitro: mapping of the binding domains A few ribosomal proteins (L11, L23, L5, L26 or S7) were previously found to bind to MDM2 and activate p53 (Lohrum et al., 2003; Zhang et al., 2003; Bhat et al., 2004; Jin et al., 2004; Ofir-Rosenfeld et al., 2008; Zhu et al., 2009 ). We, therefore, took this candidate approach and determined whether RPS27L or RPS27 would directly bind to MDM2, and if so, defined the binding motif on respective protein. Glutathione-S-transferase (GST)-fusion proteins were expressed and purified for fulllength RPS27L 1-84, the N-terminal portion, 1-36 (in which RPS27L differs from RPS27 at three AAs, codons 5, 12 and 17), the C-terminal portion 37-84 (exactly same as RPS27), the full-length RPS27 1-84 and the N-terminal portion of RPS27 1-36, along with GST control (Figure 3b ). Approximately, an equal amount of proteins were used for the pull-down assay, with His-tagged full-length MDM2 along with the empty His-tag vector control. As shown in Figure 3a , the fulllength RPS27L or RPS27 bound to MDM2, as well as the N-terminal portion, but not the C-terminal zincfinger-containing portion, although the binding was much weaker for RPS27. Thus, both the family members bind to MDM2 and the binding domain is mapped to the N-terminus (AA 1-36).
To further confirm the RPS27L-MDM2 binding at the cellular level and to define the potential RPS27L binding region on MDM2, we performed a GST pull-down experiment, using a full-length MDM2 and its deletion mutants. GST-fused full-length MDM2 (1-491) and a deletion mutant (1-301), but not the mutant 1-150 or other deletion mutants, bind to endogenous Rps27L in mouse embryonic fibroblast (MEF) cells, derived from p53-Mdm2 double-null mice (to avoid potential interference from p53) (Figure 3c ). Expression and purity of GST-fused MDM2 and its deletion mutants are shown in Figure 3d . Finally, we confirmed the binding of MDM2-RPS27L and MDM2-RPS27 using GST-MDM2 to pull down RPS27L or RPS27, produced by in vitro transcription and translation (data not shown). These results clearly demonstrated that MDM2 binds to endogenous RPS27L in the absence of p53, and that the binding region on MDM2 is from codons 151 to 293 (Figure 3c , bottom panel), an acidic domain-containing region, previously shown as the second p53-binding domain (Kulikov et al., 2006) , implying a potential competition between RPS27L/S27 and p53 for MDM2 binding.
The in vivo binding of endogenous RPS27L-MDM2 and RPS27-MDM2, and competition between RPS27L or RPS27 and p53 for MDM2 binding We further determined whether endogenous RPS27L or RPS27 binds to an endogenous MDM2, under physiological condition. Normally growing p53-null H1299 cells at the subconfluency were collected and subjected to immunoprecipitation, using antibodies against RPS27L, RPS27 or an immunoglobulin G control. As shown in Figure 4a , MDM2 can be detected in the immunoprecipitates pulled down by either RPS27L or RPS27 antibody, respectively, but not by normal immunoglobulin G control. In a reciprocal experiment, RPS27L or RPS27 can be pulled down by an antibody against MDM2 but not by the normal immunoglobulin G control ( Figure 4b ). Thus, RPS27L or RPS27 forms a complex in vivo, independent of p53. It is well established that the major p53-MDM2 binding occurs between their N-terminal domains (Kussie et al., 1996) . A second binding site at the center portion of each protein (the DNA-binding domain of p53 and the acidic domain of MDM2) was also reported (Burch et al., 2000; Kulikov et al., 2006; Shimizu et al., 2002) . As RPS27L or RPS27 binds to MDM2 on the acidic region, where it also binds to p53, we determined whether RPS27L or RPS27 competes with p53 for MDM2 binding, thus interfering the p53-MDM2 binding. We used a FLAG-tagged ligase-dead MDM2 mutant, MDM2-446/475 (Swaroop and Sun, 2003) , avoiding potential degradation of p53 or RPS27L (see below). After co-transfection with RPS27L or RPS27, FLAG-MDM2 was immunoprecipitated along with its binding partners. As shown in Figure 4c , the p53 level in MDM2 complex was significantly reduced, if either RPS27L or RPS27 was co-transfected. Likewise, in a reciprocal experiment, we found that siRNA silencing of endogenous p53 significantly enhanced the binding of RPS27L or RPS27 to MDM2-446/475 Interplays between p53-MDM2 and RPS27/S27L X Xiong et al ( Figure 4d ). Taken together, these results suggested a competition of RPS27L or RPS27 with p53 for MDM2 binding.
MDM2 regulation of RPS27L and RPS27 under overexpressed or physiological conditions
Two MDM2-binding ribosomal proteins L26 (OfirRosenfeld et al., 2008) and S7 (Zhu et al., 2009) were found to be the substrates of MDM2. We determined whether RPS27L or RPS27 is subjected to MDM2-mediated degradation. As shown in Figure 5a , when co-transfected into p53-null H1299 cells, ectopic expression of MDM2 dramatically reduced the steady-state level of exogenously expressed RPS27L (HA-S27L, lane 2 vs 1). Reduction of RPS27L requires an MDM2-acidic domain, in which the two proteins bind, and the RING E3 ligase domain, as the deletion of either of the domains abolish MDM2 activity (lanes 3 and 4). Similar results were found when MDM2 was co-transfected with RPS27 ( Figure 5b ). We further determined the potential effect of MDM2 on the protein half-life of RPS27L or RPS27. Transfected RPS27L has a half-life of B60 min, which is shortened to B30 min by MDM2 co-transfection. In contrast, RPS27 has a much longer protein half-life up to 180 min and was only moderately affected, if any, by MDM2 within the 3-h testing period ( Figure 5c ). Finally, we showed, using an immunoprecipitation assay, that MDM2 remarkably promotes polyubiquitination of RPS27L but with a minor effect on RPS27 (Figure 5d ). The results strongly suggested that although both the family members bind to MDM2, and are subjected to MDM2 degradation under overexpressed conditions, RPS27L with a much shorter protein half-life is more likely regulated by MDM2 under physiological condition. We tested this hypothesis by determining whether endogenous Rps27L or Rps27 is subjected to regulation by an endogenous Mdm2. We compared the levels of the two family members in p53-null and p53-Mdm2 doublenull MEFs. As shown in Figure 5e , the levels of Rps27L but not of Rps27 were higher in p53-Mdm2 double-null MEFs than that in p53-null MEFs, suggesting that only Rps27L is subjected to Mdm2 regulation. We followed up this finding by measuring the protein half-life of the two proteins in these two types of MEFs. As shown in Figure 5f , the protein half-life of endogenous Rps27L is about 8 h in p53-null cells, but was significantly extended up to 24 h in p53-Mdm2 double-null cells. In contrast, the half-life of Rps27 is much longer, up to 24 h, regardless of the presence of Mdm2. Taken together, these results clearly suggested that RPS27L Figure 3 The in vitro binding between RPS27L or RPS27 and MDM2, and the binding domain mapping: (a, b) direct binding of RPS27L or RPS27 to MDM2. The full-length RPS27L, RPS27, their N-terminal fragments (AA1-36) and C-terminal fragments (AA37-84) were expressed as GST-fusion proteins. The fusion proteins were purified with GSH-beads and eluted with GSH. One portion was subjected to SDS-PAGE, followed by Coomassie blue staining (b), and the other portion was subjected to binding with His-tagged-MDM2 immobilized on beads, along with the His-Tag control, followed by western blotting (IB) using anti-GST antibody (a). (c, d) The in vitro MDM2-RPS27L binding: GST-fused MDM2 (1-491) and its deletion mutants were expressed in bacteria, and purified using GSH-coated beads. About 500 ng of purified GST or GST-fusion proteins immobilized on GSH beads were used in the GST pull-down assay using cell lysates (2 mg), prepared from p53/Mdm2 double-null MEFs cells. After extensive washing, the beads were boiled, and bound Rps27L was detected by western blotting using an antibody against RPS27L (c). The levels and purity of GST-MDM2 and its deletion mutants were shown in a Coomassie blue staining gel (d).
Interplays between p53-MDM2 and RPS27/S27L X Xiong et al is a physiological substrate of MDM2, whereas RPS27, with a much longer protein half-life, can be ubiquitinated and degraded by MDM2 under overexpressed conditions.
Overexpression of RPS27L or RPS27 stabilizes p53 by inhibiting MDM2-induced p53 ubiquitination As RPS27L/S27 competes with p53 for MDM2 binding (Figure 4 ), we reasoned that its overexpression would release p53 and reduces its ubiquitination by MDM2. Indeed, in a typical in vivo ubiquitination assay, using p53-null H1299 cells, we found that p53 ubiquitination was remarkably promoted by MDM2 (Figure 6a , lane 4 vs 3), but significantly reduced by co-transfection with RPS27L (lane 5) or RPS27 (lane 6). Likewise, overexpression of either RPS27L or RPS27 caused the accumulation of endogenous wt p53 in A549 cells (Figure 6b ). Furthermore, we found that p53, when transfected alone into p53-null MEF cells, had a half-life of less than 2 h. However, when p53 was co-transfected with RPS27L, the steady-state level of p53 was much higher, and p53 half-life was extended up to B6 h (Figure 6c ). Importantly, RPS27L induced p53 increases, and half-life extension was indeed mediated by MDM2, as a similar steady-state p53 level and p53 halflife were observed when tested in p53-Mdm2 double-null MEF cells, regardless of RPS27L co-transfection (Figure 6d ). Taken together, these results strongly suggest that by binding to MDM2, thus reducing p53-MDM2 binding, RPS27L decreases MDM2-induced p53 ubiquitination, leading to increased p53 levels by extending p53 protein half-life.
SiRNA silencing of RPS27L reduces p53 levels, shortens p53 protein half-life and inhibits p53 transcription activity We further determined whether siRNA silencing of RPS27L or RPS27 would change the levels of endogenous p53. As shown in Figure 7a , lentivirus-based siRNA silencing caused a complete elimination of endogenous RPS27L and a nearly complete elimination of RPS27 in wt p53-containing A549 cells, respectively. Accompanying the silencing of RPS27L but not RPS27, the basal level of p53 was significantly decreased (Figure 7a ), which appeared to occur at the protein levels, as no change at the p53 mRNA level was observed (Figure 7b) . We, therefore, focused our study on RPS27L silencing and found that p53 reduction, upon RPS27L silencing, was MDM2 dependent, as simultaneous silencing of RPS27L and of MDM2 restored the p53 level (Figure 7c , lane 3 vs 4). Furthermore, in wt p53-containing A549 cells, siRNA silencing of RPS27L shortened the p53 half-life from B1 h to 30 min (Figure 7d) . Finally, using a p53 temperature-sensitive H1299-p53ts line (Peng et al., 2003; Robinson et al., 2003) , we found that p53 induction of p21, at the permissive temperature of 32 1C in which p53 is active, was significantly reduced upon RPS27L silencing (Figure 7e) . Likewise, p53 transcription activity, as Figure 4 The in vivo binding between endogenous RPS27L or RPS27 and endogenous MDM2, and competitive binding of RPS27L/ RPS27 with p53 for MDM2. (a) endogenous RPS27L or RPS27 binds to an endogenous MDM2: subconfluent p53-null H1299 cells were subjected to immunoprecipitation with antibody against RPS27L or RPS27, followed by western blotting with an antibody against MDM2 (a), or with antibodies against MDM2, followed by western blotting with an antibody against RPS27L or RPS27 (b).
Immunoprecipitates or whole-cell extracts (WCE) were subjected to western blotting using indicated antibodies. (c, d) The competition between RPS27L or RPS27 and p53 for MDM2 binding: a total of 293 cells were transfected with RPS27L, RPS27 or a MDM2 double-mutant K446R/C475S (446/475) alone, or in combination (c). The 293 cells were infected with lentivirus-silencing control or p53, followed by transfected with MDM2 (446/475), along with the the vector control (d). Cell lysates were prepared for immunoprecipitation using FLAG-beads. Immunoprecipitates were then subjected to western blotting using indicated antibodies. Direct western blotting of WCE is shown at the bottom panel.
Interplays between p53-MDM2 and RPS27/S27L X Xiong et al reflected by luciferase activity in a p53-driven luciferase reporter assay, was also significantly decreased upon RPS27L silencing (Figure 7f ). Taken together, RPS27L, a p53-inducible protein and a MDM2 substrate, can positively regulate p53 activity through MDM2 binding, establishing a three-way interplay among p53, MDM2 and RPS27L.
Colocalization of endogenous RPS27L with MDM2 upon DNA damage or ribosomal stress Several MDM2-binding ribosomal proteins were found to be localized in nucleolus, such as L11 (Lohrum et al., 2003; Bhat et al., 2004) and S7 (Zhu et al., 2009) , or in nucleoplasm, such as L23 Jin et al., 2004) . We determined the subcellular localization of RPS27L and its colocalization with MDM2 under unstressed or stressed conditions by immunofluorescent staining. As shown in Figure 8a , under unstressed condition, endogenous RPS27L as well as RPS27 (not shown) are mainly localized in the cytoplasm in A549 cells or in SJSA cells (data not shown), whereas Mdm2 was mainly localized in nucleoplasm, with a very low but detectable level in cytoplasm. Upon exposure of cells to different types of stress inducers, including etoposide, MI-219 (Shangary et al., 2008) , or low dose of actinomycin D that triggers ribosomal stress, a portion of RPS27L was translocated into the nucleoplasm, where it colocalized with MDM2. These stress inducers also increased the cytoplasmic MDM2 level. Western blotting analysis confirmed the induction by these stress inducers of p53 and its downstream targets, MDM2, p21 and to a lesser extent, RPS27L (except actinomycin D that failed to induce RPS27L) (Figure 8b ). Cell fractionation experiment showed that upon exposure to p53-activating signals, both the cytoplasmic and the nuclear p53, MDM2 and RPS27L (except by actinomycin D) were induced, whereas p21 induction was only detectable in the cytoplasm (Figure 8c ). These results indicate that RSP27L is mainly a cytoplasmic protein and can be translocated into the nucleoplasm, in response to p53-inducing signals, where it colocalized with MDM2, and likely competed with p53 for MDM2 binding.
SiRNA silencing of RPS27L reduces both cytoplasmic and nuclear p53 levels Finally, we determined whether RPS27L silencing would reduce p53 levels, induced by these p53-activating Figure 5 MDM2 regulation of RPS27L and RPS27 under overexpressed or physiological conditions. (a, b) Ectopic expression of RPS27L (a) or RPS27 (b) is reduced by wild-type MDM2: H1299 cells were transfected with RPS27L (a), RPS27 (b) alone, or in combination with wild-type MDM2 (wt), MDM2 acidic domain delete mutant (DA), or MDM2 Ring E3 ligase domain delete mutant (DR), followed by western blotting analysis using indicated antibodies. (c) MDM2 shortens the protein half-life of RPS27L but not RPS27: H1299 cells were transiently co-transfected with RPS27L or RPS27 alone, or in combination with MDM2. Cells were treated with cycloheximide (CHX) at 24 h after transfection for various time periods, followed by western blotting using indicated antibodies. (d) MDM2 promotes RPS27L ubiquitination: the 293 cells were transfected with indicated plasmids. At 48 h after transfection, cells were treated with MG132 for 4 h, followed by immunoprecipitation with FLAG-beads, and westen blotting with anti-HA antibody. (e, f) Regulation of endogenous Rps27L/Rps27 by endogenous Mdm2: (e) The protein level of Rps27L/Rps27: the cell lysates of p53-null and p53-Mdm2 double-null MEFs are subjected to western blotting using indicated antibodies. (f) The protein half-life of Rps27L/Rps27: cells were treated with CHX for various time periods, followed by western blotting using indicated antibodies.
Interplays between p53-MDM2 and RPS27/S27L X Xiong et al signals. Indeed, RPS27L silencing remarkably inhibited the basal and induced levels of p53 and p21 upon exposure to actinomycin D (Figure 9a ) or radiation ( Figure 9b ). Induction of p53 and its downstream targets, p21 and MDM2 by etoposide was also remarkably inhibited ( Figure 9c ). Blockage of induction of p53 and its downstream targets was not due to an overall inhibition of protein expression upon RPS27L silencing, as the expression of many other short-lived proteins, including p27, c-JUN, WEE1, IkBa and b-catenin, was not changed under the same experimental conditions (data not shown). We also observed in a cell fractionation study that RPS27L silencing reduced the levels of p53 and MDM2 in both the cytoplasm and the nucleus upon treatment with actinomycin D (Figure 9d) . Thus, the presence of RPS27L ensures the full activation of p53, consistent with our previous observation that RPS27L, upon induced by p53, amplifies p53 signals (He and Sun, 2007) . This is likely achieved by competition of RPS27L with p53 for Mdm2 binding, thus counteracting the Mdm2-p53 negative feedback loop.
Discussion
We characterized in this study the functions of an evolutionarily conserved family of ribosomal proteins, RPS27 and RPS27L, which differ by only three AAs at the N-terminus. Similarities and differences between the two family members can be summarized as follows.
First, RPS27 appears to be an oncogenic protein, with overexpression in multiple human cancer Ganger et al., 1997 Ganger et al., , 2001 Atsuta et al., 2002; Lee et al., 2004; Wang et al., 2006) or may serve as a tumor biomarker (Fernandez-Pol, 1996; Lee et al., 2004; Stack et al., 2004) , whereas RPS27L is a much less studied protein, with a known function in mediating p53-induced apoptosis (He and Sun, 2007) . Second, two proteins are subjected to p53 regulation but in an opposite direction. Although RPS27L is a direct p53-inducible gene (He and Sun, 2007; Li et al., 2007) , RPS27 is transcriptionally repressed by p53. Third, both the family members bind to MDM2 and are subjected to MDM2 degradation in a RING-and an acidic domaindependent manner when co-transfected with MDM2, but only RPS27L appears to be a physiological substrate of MDM2. Fourth, both proteins inhibit MDM2-mediated p53 ubiquitination and increase endogenous p53 levels under overexpressed condition, but only RPS27L, upon siRNA silencing, causes p53 destabilization. Taken together, our results suggest that upon p53 activation, RPS27L is induced, which in turn competes with p53 for MDM2 binding, thus reducing MDM2-mediated p53 degradation and extending p53-activating signals. On the other hand, MDM2, upon induction by p53, degrades both p53 and RPS27L to terminate p53-activating signals. Repression of RPS27 by activated p53 makes MDM2 degradation of RPS27 unnecessary under stressed conditions. Our finding that RPS27L or RPS27 binds to MDM2 by its central acidic domain, adds them into the list of other ribosomal proteins, including L5, L11, L23 and S7 Zhu et al., 2009) , known to regulate p53 activity by binding to MDM2 at the same acidic domain or adjacent zinc-finger region. However, among all MDM2-binding ribosomal proteins Interplays between p53-MDM2 and RPS27/S27L X Xiong et al that inhibit MDM2-induced p53 polyubiquitination for p53 stabilization, RPS27L and RPS27 have several unique features. First, they are the only known MDM2-binding ribosomal or ribosomal-like proteins directly subjecting to p53 transcriptional regulation, thus are directly involved in feedback regulation of p53-MDM2 axis. Second, unlike other MDM2-binding ribosomal proteins, which are localized either in the nucleolus (for example, L11 or S7) (Lohrum et al., 2003; Bhat et al., 2004; Zhu et al., 2009) or in the nucleoplasm (for example, L23) Jin et al., 2004) , RPS27L (or RPS27) is mainly localized in the cytoplasm under physiological unstressed condition in which very low level of cytoplasmic MDM2 exists. Under stressed conditions that activate p53, a portion of RPS27L is shuttled to nucleoplasm where it colocalized with an induced MDM2. As RPS27L and MDM2, in both cytoplasm and nucleus, are induced upon p53-activating signals (Figure 8c ), an induced RPS27L could compete with p53 for MDM2 binding, thus releasing/protecting p53 from MDM2-mediated degradation in both the subcellular locations, as evidenced by a reduction of p53 levels at both cytoplasm and nucleus upon treatment with actinomycin D, if RPS27L is silenced (Figure 9d ). Finally, our study showing that RPS27L is a physiological substrate of MDM2 added RPS27L into the list of ribosomal proteins, including L26 (Ofir-Rosenfeld et al., 2008) and S7 (Zhu et al., 2009) , that directly bind to MDM2 and serve as the substrates of MDM2. It is very likely that MDM2 in different subcellular compartments is responsible for the degradation of these ribosomal or ribosomal-like proteins under physiological condition or after stress stimuli. RPS27 was found to be overexpressed in many human cancers Ganger et al., 1997 Ganger et al., , 2001 Atsuta et al., 2002; Lee et al., 2004; Wang et al., 2006) . However, the underlying mechanism for its overexpression is unknown. Our study reports in this study that RPS27 is subjected to transcriptional repression by wt p53 but not by mutant p53 (Figure 2 ) may provide one logical explanation. It is well known that p53 is mutated in B50% of human cancer (Greenblatt . At 3rd day after infection, cells were collected and subjected to western blotting analysis using indicated antibodies (a) or RT-qPCR for p53 mRNA levels (b, n ¼ 2). (c) Reduction of p53 level on RPS27L siRNA silencing is abrogated by silencing of MDM2: A549 cells were infected with lentivirus-targeting RPS27L or scrambled control siRNA, then transfected with control siRNA or siRNA targeting MDM2 (SMART pool) at 24 h after infection. Cells were collected at 48 h after transfection and subjected to western blotting using indicated antibodies. (d) Shortening of p53 protein half-life: A549 cells were transfected with oligo-based siRNA targeting RPS27L or scrambled control siRNA. Cells were treated with cycloheximide (CHX) at 48 h after transfection for various time periods, followed by western blotting using indicated antibodies. LE, long exposure; SE, short exposure. (e, f) Reduction of p53 transcription activity: H1299-p53-ts model: H1299 cells stably transfected with p53138V and BP100-luc were infected with control siRNA or siRNA-targeting RPS27L for 48 h. Cells were then grown either at 32 1C for indicated periods and subjected to western blotting with indicated antibodies (e) or for 18 h and then subjected to luciferase reporter assay. Shown are mean ± s.e.m. from three independent experiments, *Po0.01 (f).
Interplays between p53-MDM2 and RPS27/S27L X Xiong et al et al., 1994) . Human cancers with p53 mutation would, therefore, likely have a higher RPS27 expression due to the loss of repression by wt p53. On the other hand, overexpressed RPS27 may in turn stabilize the mutant p53, as ectopic expression of RPS27 could increase p53 levels ( Figure 6b ). This feed-forward regulation could confer growth advantage in these cancer cells. Future study will be directed to address this interesting correlation. Our siRNA silencing study revealed that knockdown of RPS27L but not RPS27 caused destabilization of basal p53 in A549 and SJSA cells (Figures 7a and 9) , suggesting under normal physiological condition, RPS27L is the one involved in the interplay with p53-MDM2 axis. It is noteworthy, however, that in some human cancer lines with wt p53 (for example, HCT116 and U2OS) RPS27L knockdown did not destabilize p53 (data not shown). This is likely because of a higher sensitivity of these lines to unknown stresses, triggered by RPS27L knockdown to cause p53 induction, which counteracts the direct modulation of p53-MDM2 axis by RPS27L. On the other hand, it is unclear why RPS27 silencing did not destabilize p53 in A549 cells, although it binds to MDM2 and inhibits MDM2-induced p53 degradation under overexpressed condition. One possibility is that RPS27 is a housekeeping ribosomal protein whose knockdown may trigger ribosomal stress that could induce p53. It is conceivable that, compared with RPS27L, housekeeping RPS27 has a long protein halflife and is resistant to MDM2-mediated degradation under physiological or even stressed conditions. This RPS27 unique feature could confer more flexibility for cells to deal with harsh environmental conditions without stopping essential protein synthesis.
In summary, our current work, along with our previous finding (He and Sun, 2007 ), revealed a multilevel interplay between RPS27L and RPS27 family members and p53-MDM2 axis. p53 is activated upon DNA damage to transactivate MDM2 and RPS27L, and to transrepress RPS27 as well. On one hand, induced MDM2 binds to p53 and RPS27L and promotes their ubiquitination and degradation. On the other hand, induced RPS27L competes with p53 for MDM2 binding, thus releasing p53 from MDM2- , etoposide (25 mM) or MI-219 (10 mM) for 24 h, followed by immunofluorescence with indicated antibodies, and photograph was taken (a). A549 cells were treated with three agents as above. Cells were collected and whole-cell extract (WCE, 100 mg of total protein) were subjected to western blotting analysis (b) or cells were fractionated into cytoplasm and nuclear fractions and subjected (cytoplasm, 80 mg of proteins; nucleoplasm, 15-30 mg of proteins) to western blotting using indicated antibodies (c). Purity of each fractionation was determined by western blotting, detecting cytoplasmic procaspase-3 and nuclear PARP. SE, short exposure; LE, long exposure.
Interplays between p53-MDM2 and RPS27/S27L X Xiong et al mediated degradation, resulting in p53 stabilization. Through interacting with p53-MDM2 axis, RPS27L/ S27 could regulate cell growth and survival (Figure 10 ).
Materials and methods
Cell culture and drug treatment All cell lines used in this study, except for MRC5, SJSA and HCT116, were maintained in Dulbecco's modified Eagle's medium, supplemented with 10% (v/v) fetal bovine serum. MRC5 and SJSA cells were maintained in RPMI 1640 medium with 10% fetal bovine serum. HCT116 cells were maintained in McCoy's 5A medium, containing 10% fetal bovine serum.
To change p53 conformation, the temperature of the culture for H1299-p53V138A cells (H1299-ts) was either maintained at 37 1C (non-permissive for wt p53) or at 32 1C (permissive for wt). For drug treatment, subconfluent cells were incubated with actinomycin D, etoposide (Sigma, St Louis, MO, USA) and MI-219 (Shangary et al., 2008 ) (a gift from Dr Shaomeng Wang) for 24 h. The control cells were treated with dimethyl sulphoxide. Subconfluent cells were also exposed to ionizing radiation at 6 Gy, and collected at 6 or 24 h thereafter.
DNA transfection, western blotting analysis and immunoprecipitation Cells, except for MEFs, were plated onto a six-well plate at 2 Â 10 5 cells per well and transfected the following day, with a variety of plasmid using Lipofectamine 2000 (Invitrogen, , ionizing radiation (6 Gy) (b) or etoposide (25 mM) (c), followed by cell lysate preparation and western blotting analysis using indicated antibodies. A549 cells after lentivirus infection and treatment with actinomycin D were collected for cell fractionation into the cytosol and the nuclear fractions, followed by western blotting analysis using indicated antibodies (d).
p53
IR Drugs
DNA damage MDM2 RPS27L
Growth Survival RPS27 * Figure 10 A schematic model for the interplay between RPS27L/ RPS27 and p53-MDM2: DNA damage induced by ionizing radiation or chemodrugs activates p53. Activated p53, on one hand transactivates MDM2 and RPS27L, and on the other hand transrepresses RPS27. Upon induction by p53, MDM2 binds to p53 as well as RPS27L and promotes their ubiquitination and degradation, whereas induced RPS27L competes with p53 for MDM2 binding, thus releasing p53 for MDM2-mediated degradation. Under overexpressed condition (*), MDM2 also binds to RPS27 and promotes its ubiquitination and degradation, and at the same time RPS27-MDM2 binding releases p53 and reduces p53 degradation by MDM2. Through interplay with p53-MDM2 axis, RPS27L/S27 regulates cell growth and survival.
Interplays between p53-MDM2 and RPS27/S27L X Xiong et al Carlsbad, CA, USA). MEF cells were plated onto a six-well plate at 1 Â 10 6 cells per well and transfected with indicated plasmids using PolyJet DNA transfection reagent (Signagen Laboratories, Ijamsville, MD, USA). Cells were collected, lysed and subjected to western blotting analysis and immunoprecipitation as described (Tan et al., 2008) , using various antibodies as follows: p53 (Ab-6, Calbiochem, San Diego, CA, USA), HA (Roche, Indianapolis, IN, USA), FLAG and b-actin, (Sigma), MDM2 (Ab-1, Calbiochem; 2A9, gift from Jiandong Chen; N-20 and SMP14 from Santa Cruz Biotechnology, Santa Cruz, CA, USA) and p21 (BD Pharmingen, San Jose, CA, USA). RPS27L or RPS27 polyclonal rabbit antibody was raised and purified as described (He and Sun, 2007) . The antigenic peptides used to generate these two antibodies are RL-S27L: MPLARDLLHPSLEEC (for RPS27L) and KP-S27: MPLAKDLLHPSPEEC (for RPS27), respectively, differing in two AAs from each other. After two runs of affinity purification and affinity absorption, the specificity of two antibodies were tested and confirmed in cells overexpressing each protein (Figure 1c ).
Pull-down assay
Two types of pull-down assays were performed. First, fulllength RPS27L, RPS27, and their N-terminal fragments (AA1-36) and C-terminal fragments (AA37-84) were expressed as GST-fusion proteins. The fusion proteins were purified with GSH-beads and eluted with GSH. Purified GST-tagged RPS27L/S27 proteins were then incubated with His-tagged-MDM2, immobilized on beads, along with the His-Tag control, followed by western blotting using anti-GST antibody. Second, GST-fused MDM2 (1-491) and its deletion mutants were expressed in bacteria, and purified using GSHcoated beads. About 500 ng of purified GST or GST-fusion proteins immobilized on GSH beads were used to incubate with cell lysates (2 mg), prepared from p53-Mdm2 double-null MEFs cells in a pull-down assay. After extensive washing, the beads were boiled and bound Rps27L was detected by western blotting analysis. 0 . Cells were infected and split, followed by assays as described (Jia et al., 2009) . To silence the endogenous wt p53, cells were infected with a lentivirus-based scrambled control siRNA, or LT-p53-siRNA as described . The pooled siRNA oligos targeting MDM2 (SMART pool) were purchased from Dharmacon, Lafayette, CO, USA.
Lentivirus-based siRNA and lentivirus infection
In vivo ubiquitination assay Human lung H1299 cells were transiently transfected with various plasmids and collected at 24 h after transfection, and split into two aliquots, with one for direct western blotting analysis and the other for in vivo ubiquitination assay as described (Gu et al., 2007) . Briefly, cell pellets were lysed in buffer A (6 mol/l guanidinium-HCl, 0.1 mol/l Na 2 HPO 4 / NaH 2 PO 4 , 10 mmol/l Tris-HCl (pH 8.0), 10 mmol/l b-mercaptoethanol) and incubated with Ni-NTA beads (Qiagen, Valencia, CA, USA) at room temperature for 4 h. Beads were washed once with each of buffer A, buffer B (8 mol/l urea, 0.1 mol/l Na 2 HPO 4 /NaH 2 PO 4 , 10 mmol/l Tris-HCl (pH 8.0), 10 mmol/l b-mercaptoethanol) and buffer C (8 mol/l urea, 0.1 mol/l Na 2 HPO 4 /NaH 2 PO 4 , 10 mmol/l Tris-HCl (pH 6.3) and 10 mmol/l b-mercaptoethanol). Proteins were eluted from beads with buffer D (200 mmol/l imidazole, 0.15 mol/l TrisHCl (pH 6.7), 30% glycerol, 0.72 M b-mercaptoethanol, 5% sodium dodecyl sulfate). The eluted proteins were analyzed by western blotting for polyubiquitination of p53 with anti-p53 antibody.
Quantitative RT-PCR Total RNA was isolated from cells using a TRIzol kit (Invitrogen), and subjected to quantitative RT-PCR analysis, according to the manufacturer's instruction of QuantiTect SYBR green RT-PCR kit (Qiagen). Cycling program was set as following: 50 1C for 30 min at room temperature, 95 1C for 15 min for the PCR initial activation and 40 cycles of denaturation at 94 1C for 15 s, annealing at 55 1C for 30 s and extension at 72 1C for 30 s. The sequences of RPS27, p53 and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) are as follows: hu-p53 F1: TCTGTGACTTGCACGTAC, hu-p53 R1: ATTTCCTTCCACTCGGAT; RPS27 F1: GAGAACAT GCCTCTCGCAAA, RPS27 R1: CTCCTGAAGGAACATC CTTCT; GAPDH-F1: GTTGCCATCAATGACCCCTT, GA PDH-R1: AGAGGCAGGGATGATGTTCT.
Luciferase reporter assay H1299-ts cells, (Robinson et al., 2003) stably transfected with a p53-responsive BP100-luc reporter (Peng et al., 2003) , were infected with control siRNA or siRNA-targeting RPS27L, and then split and grown at 32 1C for 18 h, followed by luciferase reporter assay (Promega, Madison, WI, USA). The results are presented as the fold change, with the value of siConttransfected cells arbitrarily set as 1.
Immunofluorescent staining A549 cells were left untreated or treated for 24 h with the ribosomal stress inducer, actinomycin D (5 nM), DNA-damaging agent, etoposide (25 mM) or MI-219 (10 mM), a smallmolecule compound that disrupts p53-MDM2 binding to activate p53, followed by MDM2 accumulation (Shangary et al., 2008) . Cells were then immunostained with indicated antibodies, and photographed (Jia et al., 2009) .
Cellular fractionation
After various drug treatments, cells were collected and rinsed with buffer A (10 mM HEPES-K þ , pH 7.5, 10 mM KCl, 1.5 mM MgCl 2 , 0.5 mM DTT and protease inhibitor cocktail). The cells were then lysed in 0.5% NP-40-containing buffer A for 10 min. The supernatant was collected as cytoplasm protein by spinning at 3000 r.p.m. for 2 min at 4 1C. The nuclear pellets were washed with buffer A, followed by re-suspending in buffer B (20 mM HEPES-K þ , pH 7.9, 420 mM NaCl, 0.2 mM EDTA, 1.5 mM MgCl 2 , 0.5 mM DTT, 25% glycerol and protease inhibitor cocktail), and incubated on ice for 30 min. Supernatant-containing nuclear protein were collected by spinning at 14 500 r.p.m. for 10 min at 4 1C.
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